FDA-Approved Inhibitors of RTK/Raf Signaling Potently Impair Multiple Steps of In Vitro and Ex Vivo Influenza A Virus Infections

FDA-Approved Inhibitors of RTK/Raf Signaling Potently Impair Multiple Steps of In Vitro and Ex Vivo Influenza A Virus Infections

Influenza virus (IV) infections pose a burden on global public health with significant morbidity and mortality. The limited range of currently licensed IV antiviral drugs is susceptible to the rapid rise of resistant viruses. In contrast, FDA-approved kinase inhibitors can be repurposed as fast-trac...

Full description

Bibliographic Details
Main Authors: Robert Meineke, Sonja Stelz, Maximilian Busch, Christopher Werlein, Mark Kühnel, Danny Jonigk, Guus F. Rimmelzwaan, Husni Elbahesh
Format: Article
Language:English
Published: MDPI AG 2022-09-01
Series:Viruses
Subjects:
influenza
antivirals
kinases
innate immunity
respiratory viruses
inhibitors
Online Access:https://www.mdpi.com/1999-4915/14/9/2058

Internet

https://www.mdpi.com/1999-4915/14/9/2058

Similar Items